EGRX - Eagle Pharmaceuticals Investigated by Block & Leviton for Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
Boston, Massachusetts--(Newsfile Corp. - December 1, 2023) - Block & Leviton is investigating Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) for potential securities law violations. Investors who have lost money in their Eagle Pharmaceuticals, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/egrx.
What is this all about?
On November 29, 2023, Eagle Pharmaceuticals announced the resignation of Chief Executive Officer, Scott Tarriff. Tarriff has been the CEO of the Company since its inception in January of 2007.
Shares of Eagle Pharmaceuticals stock dropped more than 27% in intraday trading on November 29, 2023.
Who is eligible?
Anyone who purchased Eagle Pharmaceuticals, Inc. stock and has lost money may be eligible, whether or not they have sold their investment. Investors should contact Block & Leviton to learn more.
What is Block & Leviton doing?
Block & Leviton is investigating whether the Company committed securities law violations and may file an action to attempt to recover losses on behalf of investors who have lost money.
What should you do next?
If you've lost money on your investment, you should contact Block & Leviton to learn more via our case website, by email at cases@blockleviton.com, or by phone at (617) 398-5600.
Why should you contact Block & Leviton?
Block & Leviton is widely regarded as one of the leading securities class action firms in the country. We have obtained, and are dedicated to obtaining significant recoveries on behalf of defrauded investors through active litigation in the federal courts across the country. Many of the nation's top institutional investors hire us to represent their interests. You can learn more about us at our website, www.blockleviton.com, or call (617) 398-5600 or email cases@blockleviton.com with any questions.
This notice may constitute attorney advertising.
CONTACT:
BLOCK & LEVITON LLP
260 Franklin St., Suite 1860
Boston, MA 02110
Phone: (617) 398-5600
Email: cases@blockleviton.com
SOURCE: Block & Leviton LLP
www.blockleviton.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/189484